Three hot topics of 2019 China biomedical innovation and cooperation conference are open!

It is sponsored by Wanyi medicine and co sponsored by the business office of the U.S Embassy and consulate in China, the British Department of international trade, Shanghai Biomedical Industry Association, Shanghai Pudong New Area Biomedical Industry Association, Shanghai junrun Network Technology Co., Ltd., and has obtained Baihua Association, Hong Kong Biotechnology Association, new drug founder club, Shanghai equity investment Association, Guangdong Medical Valley, Wuhan Donghu national self With the strong support of the biomedical industry association, Yaodu, touhu.com, tongshuyi, Haimen Science Park, etc in the main innovation demonstration area, 2019 China biomedical innovation cooperation conference will be held in Dahua splendid holiday hotel, Pudong, Shanghai from September 26 to 27 The three hot topics and guest lineup were announced first Scan the QR code below to sign up for the meeting and get more exciting content! Standard registration fee more group discounts and sponsorship programs, please contact the organizing committee staff at the end of the article At present, there are only two booths and one speaking opportunity left Please book as soon as possible! Topic 1: explore the development and innovation cooperation mode of antibody in tumor immunotherapy at present, one of the most widely used fields of antibody drugs in clinical treatment is anti-tumor From the first anti-tumor antibody drug rituximab (Roche) was launched in 1997, to November 2018, 35 anti-tumor antibody drugs have been approved (excluding delisted drugs), accounting for more than 40% of all antibody drugs With the development of new antibody drugs and the continuous expansion of the indications of antibody drugs on the market in the field of cancer, how can major pharmaceutical companies achieve win-win cooperation and promote the development process of antibody drugs? Mr Tian Wenzhi, chairman and general manager of yimingongke, Mr Zheng Biao, chief scientific officer of JinFang pharmaceutical, Mr Liao maijing, chief commercial officer of platinum pharmaceutical, Mr Yang Jianxin, chief medical officer of cornerstone pharmaceutical, Mr Chen Hongkai, founder and chief executive of elixion immunotherapeutics, will jointly look for the future development direction of biomedical enterprises in the current situation at the conference on September 26 And innovative cooperation mode Topic 2: development, application and clinical application of car-t products chimeric antigen receptor T cells (car-t cells) therapy is one of the hottest fields of anti-tumor immunity, and also a major breakthrough in immunology in the past decade From the development of the first generation of car-t cells based on CD3 ζ chain in 1993 to kymriah becoming the first auto cell car-t therapy in the world in 2017, the development of car-t cells is not smooth Although the second generation of car-t cells has a good effect on hematological malignancies and is the mainstream in the field of car-t, the development of the third and fourth generation of car-t cells is not perfect, and there are many problems to be solved Mr Zhang Jishuai, founder of prekin bio pharmaceutical, Mr Cao Wei, CEO of Genxi bio, Mr Sun Wenjun, vice president of business development and government affairs of yaomingjuno, Mr Liu Mingyao, Dean of School of life sciences of East China Normal University and chief scientist of bangyao bio, Ms LV Lulu, CEO of Heyuan Bio, chief scientist and Chang of hengruiyuan zhengbio Technology Co., Ltd Mr Zhou Xiangjun, vice general manager, will conduct a fierce brainstorming from the perspectives of the challenges in safety, commercialization, solid tumor treatment and supervision of car-t cell therapy Topic 3: the research and development difficulties and market prospects of macromolecular bio innovative drugs compared with the indication extension and replaceability of small molecular generic drugs, the development of bio innovative drugs is quite difficult and challenging for developers and regulators due to their complex structure In addition, due to the complex production process and quality control, large initial workshop investment and high clinical costs, the sales price of macromolecular drugs will not be as low as that of chemical drugs and generic drugs, and the innovation of business model is needed in marketing promotion In view of the R & D difficulties and market prospects of macromolecular bio innovative drugs, Ms Wei Ziping, co-founder, chairman and CEO of bailisikang bio Pharmaceutical Co., Ltd., Mr Chen Zhaorong, chief medical officer of Xikang bio Pharmaceutical Co., Ltd., Mr Wang Minghan, founder, chairman and CEO of Vance bio Pharmaceutical Co., Ltd., and global clinical R & D executive of sanyezao bio Pharmaceutical Co., Ltd Ms Dong min, vice president, will also gather at the conference on September 26 to discuss the progress of Chinese Biomedical enterprises in macromolecular innovative drugs Contact: Sponsor / exhibitor: Mr Xiao danielxiao@healife.com + 8613917465409 attending / media cooperation: Ms Xu anniexu@healife.com + 8618621654360 official website: http://